



Pioneering science delivers vital medicines™



# Amgen BC Quick Facts

Amgen believes in the transformative power of science to bring the benefits of biotechnology to more people than ever before. Amgen's Canadian research facility in Burnaby, British Columbia plays an important role in contributing to our 27-year legacy as a global leader in the identification, isolation, production and use of human proteins as therapeutic agents. The Amgen commercial team in BC works in partnership with the provincial government and other stakeholders to bring practical, cost-effective and long-term improvements to the healthcare system in British Columbia.

Today, Amgen scientists in Burnaby work on the cutting edge between the traditional disciplines of chemistry, cellular and molecular biology in an effort to discover and develop pioneering medical treatments. Amgen research leverages new scientific breakthroughs for patient care – from the laboratory to treatment – faster and safer than ever before, helping patients in their fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses.

## Amgen BC's Innovative Technology

Amgen BC's research centre is a custom-built, state-of-the-art laboratory, incorporating novel, proprietary technologies to isolate, develop and produce potential medicines. This world-class biotechnology lab enables Amgen BC to produce superior research results that translate into better therapeutic treatments.

Key to Amgen BC's leadership in biotechnology is the company's focus on advancing Amgen's most promising, innovative, potential new therapeutics into clinical studies, while significantly expanding the organization's understanding of the underlying causes of diseases

Amgen BC's cutting-edge XenoMouse™ technology produces human antibodies that can be refined for therapeutic treatment. The complementary XenoMax™ process and proprietary SLAM technology accelerate the ability to identify the best potential research candidates and isolate individual cells for further study. These progressive research tactics mean Amgen BC identifies the most promising antibody candidates far earlier in the research and development timeline than before.

### QUICK FACTS

**Location:** Burnaby, British Columbia

**Staff:**

Burnaby – 55  
Commercial Field staff – 11

**Key Functions:**

- Research and Development
- Commercial Operations

**Address/Phone**

Amgen British Columbia Inc.  
7990 Enterprise Street  
Burnaby, British Columbia  
Canada V5A 1V7  
Phone: (604) 676-8300

### HISTORY IN BC

- 1991 – Amgen Canada is established
- 1993 – ImmGenics Pharmaceuticals Inc. is founded in British Columbia
- 1999 – Abgenix licenses Amgen to use its XenoMouse™ technology
- 2000 – Abgenix acquires ImmGenics and SLAM technology developed by UBC's Biomedical Research Centre
- 2002 – Abgenix and Amgen enter co-development agreement for panitumumab
- 2004 – The current research and development facility in Burnaby is completed
- 2006 – Amgen acquires Abgenix, Inc., including its Burnaby R&D group
- 2008 – Launch of Vectibix®
- 2009 – Launch of Nplate™

### PRIMARY THERAPEUTIC CATEGORIES

- Cancer
- Kidney Disease
- Severe Inflammation

## AMGEN BC PARTNERSHIPS

### Educational Institutions

- University of British Columbia
- Simon Fraser University
- BC Institute of Technology
- University of Victoria
- University of Northern BC

### Organizations

- LifeSciences BC
- Rx&D
- Post-Consumer Pharmaceutical Stewardship Association

## ABOUT AMGEN

Amgen (NASDAQ: AMGN) discovers, develops and delivers innovative human therapeutics. Amgen's mission is to serve patients. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing novel medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.

Formed in 1991, Amgen Canada is based in Mississauga, Ontario. Today there are approximately 400 Amgen employees in Canada with approximately 75 based in British Columbia.

Headquartered in Southern California and with offices in 35 countries, Amgen has nearly 20,000 staff members worldwide. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit [www.amgen.com](http://www.amgen.com).

## Commitment to British Columbia

Amgen believes that biologic medicines have the power to change the ways we can fight disease and promote health, and the exciting scientific research being conducted in British Columbia is leading the way. Amgen's leadership in biotherapeutic research is underscored by its corporate commitment to re-investing sales revenue back into research in Canada. The Burnaby facility represents a robust and ongoing investment in the BC biosciences industry.

Many of Amgen BC's proprietary research innovations were developed or invented in BC – a testament to the tremendous scientific talent pool that has been trained here and works in this province. Amgen strives to attract the best and brightest minds from British Columbia's post-secondary and graduate science education programs. The company also believes in investing in tomorrow's great scientists, providing nurturing opportunities for aspiring students to gain solid work experience through active participation in BC's co-operative education programs and other science education and mentoring programs.

Amgen BC is involved in the community, and is proud to contribute to a number of worthwhile causes in the province including the Burnaby Hospital Foundation's Patient Education Centre. Amgen is also committed to raising the value of science literacy in the community; attracting bright young minds into the field of science by supporting educations; and improving access to science resources. One key program is the annual Amgen Awards for Science Teaching Excellence, which recognizes extraordinary contributions by educators in British Columbia. Amgen also directs its corporate giving to research efforts and patient support groups, particularly in the areas of Oncology, Bone Health, Inflammation and Nephrology.

## Amgen Medicines Available in British Columbia

**Aranesp®** (darbepoetin alfa) is prescribed for the treatment of anemia associated with chronic kidney disease. It is also prescribed for the treatment of anemia in patients with non-myeloid malignancies, where anemia is due to the effect of concomitantly administered chemotherapy.

**Enbrel®** (etanercept) is prescribed for the treatment of moderately-to-severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis (arthritis of the spine) and chronic moderate to severe plaque psoriasis.

**Neulasta®** (pegfilgrastim) or **NEUPOGEN®** (filgrastim) is prescribed to reduce the incidence of infection (initially marked by a low white blood cell count and fever) in certain cancer patients who are receiving chemotherapy that could decrease their number of infection-fighting white blood cells. Neulasta® is a longer-acting form of NEUPOGEN® that requires only one injection per chemotherapy cycle.

**Sensipar®** (cinacalcet HCl) is an oral therapy prescribed to treat hyperparathyroidism caused by chronic kidney disease; it is approved for use in patients with chronic kidney disease receiving dialysis.

**Vectibix®** (panitumumab) is indicated as monotherapy for the treatment of patients with EGFR-expressing metastatic colorectal carcinoma with non-mutated (wild-type) *KRAS* after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

